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Table
Patient Ancestry 8/8 URD 7/8 URD dCB No 7-8/8 URD/dCB
Europeans
N[ 605
397/605 (66%) 97/605 (16%) 103/605 (17%) 8/605 (1%)
Non-Europeans
N[ 279
74/279 (26.5%) 55/279 (20%) 115/279 (41%) 35/279 (12.5%)
African (n ¼ 95) 10/95 (11%) 24/95 (25%) 37/95 (39%) 24/95 (25%)
White Hispanic (n ¼ 59) 16/59 (27%) 17/59 (29%) 19/59 (32%) 7/59 (12%)
Asian (n ¼ 66) 20/66 (30%) 8/66 (12%) 37/66 (56%) 1/66 (1%)
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given priority if available; otherwise HLA-mismatched URDs
or double-unit CB (dCB) grafts were chosen.
Results: Of 884 patients, 623 (70%) received a 7-8/8 URD
transplant, 218 (25%) underwent dCBT & 43 (5%) had no URD/
dCB graft. The distribution of 8/8 URD, 7/8 URD, dCB & no URD/
dCB grafts is shown (Table). The majority (66%) of Europeans
received an 8/8 URD whereas the majority of non-Europeans
received either a mismatched URD or dCB graft. 35/43 (81%) of
patients without URD/CB grafts had non-European origins, &
no URD/dCB grafts were seen in 1% of Europeans versus 12.5%
of non-Europeans. When non-Europeans were subdivided
into the largest minority groups we found African, White
Hispanic & Asian patients were very unlikely to have a
matched URD, were most likely to receive dCB grafts, &
African ancestry patients were the most likely (one quarter) to
have no URD or dCB graft. Interestingly, there was no
difference in 8 allele donor recipient HLA-match grade of
European (median 5/8, range 2/8-8/8) & non-European
(median 5/8, range 1/8-8/8) dCBT recipients. When the origin
of dCB grafts was analyzed we found that overall 71% of units
for European ancestry patients were domestic as compared to
78% of units for non-Europeans. However, in African & white
Hispanic patients 86% & 83% of CB units were obtained from
the domestic inventory, respectively.
Conclusion: CB extends transplant access to all patients & is
especially important for minorities who are unlikely to have
a matched URD. The fact that over 80% of units used in Af-
rican & white Hispanic patients were domestic, that these
patients will be very unlikely to identify a matched URD
regardless of the size of the global volunteer donor registry, &
that some minority patients do not have suitable CB grafts
emphasizes the critical importance of the funding of US
public CB banks.190
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A major challenge in unrelated hematopoietic cell trans-
plantation (HCT) is the prediction of permissive HLA mis-
matches, i.e. those associated with lower clinical risks
compared to their non-permissive counterparts. For HLA-
DPB1, a clinically prognostic model has been shown to be
matching for T-cell epitope (TCE) groups assigned by cross-
reactivity of T-cells alloreactive to HLA-DPB1*09:01, however
the molecular basis of this observation is not fullyunderstood. Here we have mutated amino acids (aa) in 10
positions of HLA-DPB1*09:01 to other naturally occurring
variants, expressed them by lentiviral vectors in B cell lines
and quantitatively measured allorecognition by 17 CD4+ T-
cell effectors from 6 unrelated individuals. A signiﬁcant
impact on the median alloresponse was observed for peptide
contact positions 9, 11, 35, 55, 69, 76 and 84, but not for
positions 8, 56 and 57 pointing away from the groove. A score
for the “functional distance” (FD) from HLA-DPB1*09:01 was
deﬁned as the sum of the median impact of polymorphic aa
in a given HLA-DPB1 allele on T-cell alloreactivity. Estab-
lished TCE group assignment of 23 alleles correlated with FD
scores of 0.5, 0.6-1.9 and 2 for TCE groups 1, 2 and 3,
respectively. Based on this, prediction of TCE group assign-
ment will be possible for any given HLA-DPB1 allele. In silico
TCE group classiﬁcation was performed for currently 328
HLA-DPB1 alleles encoding distinct proteins for which T-cell
crossreactivity patterns are unknown, with subsequent
functional conﬁrmation for 7/7 of them. These ﬁndings have
practical implications for the applicability of TCE group
matching in unrelated HCT, and provide new insights into
the molecular mechanisms underlying this model. The
innovative concept of FD opens new potential avenues for
risk prediction in unrelated HCT.191
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Topic Signiﬁcance & Study Purpose/Background/Ratio-
nale: HLA haploidentical stem cell transplantation (SCT)
has expanded donor sources from family members. Never-
theless, some patients have no donor candidate and no time
to select a suitable donor, especially in post-transplant
relapse or rejection. In kidney or liver transplantation, on the
other hand, spousal transplant has been routinely per-
formed. In this study, we presented six cases of spousal SCT
for post-transplant relapse/rejection, and discussed the
possibility of spousal SCT.
Methods, Intervention, & Analysis: Six patients (M/F 4/2,
25-53 years old) underwent SCT from their spouse at Hyogo
College of Medicine between October 2008 and November
2013permissionof IRB.Original diseaseswereacute leukemia
(AML 2, ALL 2, MLL 1) and one case of NHL. All patients
received a third SCT for post-transplant relapse except for one
undergoing SCT for graft rejection after unrelated SCT. HLA
disparity in GVH/HVG directions were 2/4, 3/3, 2/2, 5/6, 2/1,
and 3/3 antigens in HLA A, B, DR. The conditioning regimen
consisted of FLU/MEL/ATG with or without 3 Gy of TBI for
relapse cases, and ATG plus 4 Gy of TBI for the rejection case.
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tacrolimus, 1 mg/kg/day of methylprednisolone, and 15 mg/
kg/day ofMMF. PBSC containing 1.78-8.46 * 10e6/kg of CD34+
cells were transplanted in all cases.
Findings & Interpretation: Granulocyte engraftment was
achieved on days 9-11 in all cases. Complete spousal chi-
merism in PB was conﬁrmed on days 3-13 by STR-PCR.
Acute GVHD was controllable except in the rejection case,
who died of grade IV GVHD on day 39. All ﬁve relapse
cases achieved complete remission once, and three could
be discharged. One patient died of VOD/SOS on day 62, and
one patient was transferred to her local hospital. The
remaining four patients excluding GVHD and VOD/SOS
cases ﬁnally developed disease relapse (in BM 2, CNS 2) on
days 106-334, and died as a direct result on days 152-548.
Discussion & Implications: Since these cases are refractory
and they received their third SCT, we cannot refer to the
GVL effect, and GVHD would be acceptable in spousal SCT.
The immune recovery remains to be elucidated over a
long-term follow-up.192
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In a pilot study, we carried out Haploidentical trans-
plantation for 10 patients with severe aplastic anemia (SAA)
using peripheral blood stem cell (PBSC) graft and post-
transplantation cyclophosphamide (PTCY). The conditioning
comprised of Fludarabine 150 mg/m2, CY 30 mg/kg, horse
ATG 45 mg/kg and Melphalan 120 mg/m2, followed by PTCY
50 mg /kg on D+3, +4 and cyclosporine and mycophenolate
from D + 5. Prompt engraftment was followed by early
alloreactivity, resulting in transplant-relatedmortality in 4 of
the ﬁrst 5 patients, all with NK Ligandmismatched donors. In
the subsequent 5 patients, Sirolimus was introduced from
Day -7 to maintain a trough level of 8-14 ng/ml on the day of
transplant and was continued for 12months post-transplant,
with a reduced trough level for cyclosporine. All 5 patients
had prompt engraftment with 78-100% donor chimerism
and mild chronic GVHD in one patient only. The only sig-
niﬁcant toxicity observed in these patients was Sirolimus
associated acneform lesions. Analysis of Regulatory T cells at
45 days posttransplant was 0.09  0.13% in the ﬁrst 3/5 pa-
tients compared to 2.6  0.77% in those receiving Sirolimus
(p¼0.001). Our study demonstrates that NK cell ligand mis-
matched donors are associated with early alloreactivity
following Haploidentical PBSC transplantation for SAA but
addition of Sirolimus to PTCY improves tolerance and out-
come.193
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Background: Almost 1% of the Japanese population has HLA-
homozygous haplotypes (the same HLA haplotypes). An HLA
mismatch between patients with HLA-homozygous haplo-
types and their children or parents is absent in the graft-
versus-host (GVH) direction. Hematopoietic stem cell
transplantation (SCT) from a haploidentical donor with HLA
mismatch only in the host-versus-graft (HVG) direction was
feasible using standard GVHD prophylaxis (Ikegame K, et al.
IJH 2012). However, this should be validated in a larger
cohort.
Methods: We analyzed 229 patients with hematologic ma-
lignancies who had homozygous HLA-A, -B, and -DR antigens
and received their ﬁrst allogeneic SCT from a related donor
without an HLA mismatch in the GVH direction between
1998 and 2012 in Japan. In total, 155 patients received SCT
from an HLA-matched related donor (homo-to-homo SCT)
and 74 received SCT from a haploidentical donor with HLA
mismatch only in the HVG direction (hetero-to-homo SCT).
High-risk disease and the use of tacrolimus were more
frequently observed in the hetero-to-homo SCT group. The
number of HLA mismatches in the HVG direction was 1 in 16
patients, 2 in 27 patients, and 3 in 31 patients. The impact of
hetero-to-homo versus homo-to-homo SCT was analyzed
after adjusting for transplant year, age, and other signiﬁcant
variables.
Results: There was no signiﬁcant difference in the cumu-
lative incidence of neutrophil engraftment and severe
acute GVHD between the hetero-to-homo and homo-to-
homo SCT groups (neutrophil engraftment at 50 days, 91%
vs. 95%; adjusted hazard ratio (aHR) 1.05, P ¼ 0.768; se-
vere acute GVHD at 100 days, 10% vs. 5%; aHR 1.68, P ¼
0.320). Non-relapse mortality was signiﬁcantly higher in
the hetero-to-homo SCT group than in the homo-to-homo
SCT group (26% vs. 10% at 5 years; aHR 2.42, P ¼ 0.013),
whereas there was no signiﬁcant difference in the relapse
rate. This resulted in non-signiﬁcant lower overall survival
in the hetero-to-homo SCT group (35% vs. 57% at 5 years;
aHR 1.41, P ¼ 0.083).
Conclusions: Hetero-to-homo SCT is usually considered
only when transplantation should be performed immedi-
ately for high-risk disease. Therefore, differences in patient
background between the homo-to-homo and hetero-to-
homo SCT groups may have biased the comparison. How-
ever, it should be noted that there was no signiﬁcant
difference in neutrophil engraftment as well as severe acute
GVHD. Although non-relapse mortality and overall mortal-
ity rates were higher in the hetero-to-homo SCT group than
